SCHEMBL20176009

SCHEMBL20176009

Cc1ccc(/C=C/c2cnc3c(O)cccc3c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.62
CD74 P04233 1/20 0.44
MIF P14174 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
HTT P42858 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
ALOX5 P09917 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18573144 0.86 KDM4E (0.57) KDM4ECD74MIFMEN1KMT2A
SCHEMBL20176001 0.79 COMT (0.59) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL1787225 0.77 KDM4E (1.00) KDM4EMEN1KMT2AMMP2CHRM1
SCHEMBL20176003 0.77 KDM4E (0.73) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL29957261 0.76 KDM4E (0.57) KDM4EMEN1KMT2ANPC1MMP2
SCHEMBL28490536 0.76 KDM4E (0.57) KDM4EMEN1KMT2ANPC1MMP2
SCHEMBL9970473 0.76 CCR1 (0.50) KDM4EMAPTRELAPDGFRBPDGFRA
SCHEMBL27824094 0.76 KDM4E (0.96) KDM4EMEN1KMT2AMMP2CHRM1
Hydrochloric Acid SCHEMBL9333864 0.76 KDM4E (0.96) KDM4EMEN1KMT2AMMP2CHRM1
SCHEMBL9732094 0.75 KDM4E (0.49) KDM4EMEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141911-A1 Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease NORTHEASTERN UNIVERSITY 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141911-A1 Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease MAPT, PSEN1, PSEN2 KDM4E 3865/4885CD74 4324/4885MIF 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.